Effects of Peanut Consumption on Adults With Metabolic Associated Fatty Liver Disease

Impacts of Peanut Intake on Hepatic Markers and Gut Microbiota in Adults With MASLD

The aim of this randomized interventional trial is to understand the effects of peanut consumption on patients with metabolic associated fatty liver. The main goal is to investigate if patients who consume peanuts have improved liver marker tests as well as metabolic profile. We will also investigate how peanuts alter the gut microbes and liver fat content in patients with metabolic associated fatty liver.

• Participants will be randomized into intervention (peanut consumption for 12 weeks) and control (regular diet) arm.
• Stool sample and blood (for biomarkers) collection across both arms at baseline and post-intervention
• Daily log to be completed for tracking peanut consumption
• 2-day Dietary recall at baseline, during Week 6 and Week 12
• Poat intervention Fibro scans for participants with baseline scans available

Inclusion Criteria:

• 30-70 years
• do not consume peanut/peanut butter/treenut/seeds > /week
• at least one encounter-related (stage F0/F1) MASLD diagnosis (K76.0)
• Able to understand, speak, and read English
• Mentally competent to consent

Exclusion Criteria:

• Food allergy to peanuts or peanut-containing products
• With alcohol use disorder (AUDIT screening)
• Leukemia
• Lymphoma
• Other types of cancer
• Heart or cardiovascular diseases (such as heart attack, stroke, heart failure)
• Kidney diseases (such as chronic kidney disease, kidney transplant, renal insufficiency such as renal failure requiring dialysis)